Jul. 7 at 5:08 PM
I looked into FCX-007 d-fi by Creek Biosciences which could get fda approval in mid 2027 if the phase 3 trial which is ongoing is good. the problem here is the drug was tested in wounds up to 34cm2 and the phase 3 trial is only for wounds up to 10cm2 which implies the medium sized wounds didn't do well. it is only going after very small wounds. this is untenable with such an invasive procedure.
$ABEO $KRYS
abeona is good for large wounds
krystal is good for medium smaller wounds who don't want an invasive procedure
creek biosciences doesn't have anything.
